Annovis Bio (ANVS)
(Delayed Data from NYSE)
$9.14 USD
+1.16 (14.54%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $9.10 -0.04 (-0.44%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for Annovis Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 26 | 15 | 7 | 2 |
Income After Depreciation & Amortization | -45 | -26 | -15 | -7 | -2 |
Non-Operating Income | -11 | 0 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -56 | -25 | -14 | -5 | -1 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -56 | -25 | -14 | -5 | -1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -56 | -25 | -14 | -5 | -1 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -45 | -26 | -15 | -7 | -2 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -45 | -26 | -15 | -7 | -2 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 9.02 | 8.16 | 7.63 | 6.31 | NA |
Diluted EPS Before Non-Recurring Items | -4.92 | -3.10 | -1.90 | -0.87 | NA |
Diluted Net EPS (GAAP) | -6.23 | -3.10 | -1.90 | -0.87 | -3.51 |
Fiscal Year end for Annovis Bio, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.77 | 7.80 | 10.44 | 14.87 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.77 | -7.80 | -10.44 | -14.87 |
Non-Operating Income | NA | 2.74 | 6.74 | 0.07 | 0.15 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -5.02 | -1.07 | -22.21 | -14.72 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.02 | -1.07 | -22.21 | -14.72 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.02 | -1.07 | -22.21 | -14.72 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 11.31 | 10.83 | 9.53 | 9.01 |
Diluted EPS Before Non-Recurring Items | NA | -0.44 | -0.72 | -1.09 | -1.63 |
Diluted Net EPS (GAAP) | NA | -0.44 | -0.72 | -2.34 | -1.63 |